动物造模 z-bio 2022-11-22 375

　　Objective: Elotinib is a new targeted drug for the treatment of non-small cell lung cancer. In recent years, it has been widely used in clinical practice, but there are many side effects, among which rash is the most common, and it is most difficult for patients to accept. The purpose of this study is to observe the changes in the epidermis, pathology, immunohistochemistry and other aspects of mice before and after the application of Trocay, and to duplicate the animal model of rash caused by Trocay, so as to provide a model for clinical topical drug treatment of rash.

　　Methods: Twenty BALB/c female mice were randomly divided into four groups. The experimental group (Group Ⅱ, Ⅲ, Ⅳ) was given 100 mg/kg Trocaine solution with a concentration of 10 g/L by gavage, and the control group (Group Ⅰ) was given the same volume of deionized water by gavage once a day. Hair was removed from the head, neck, back and waist of the mice 24 hours before administration. After the experiment, the skin of the neck, back and waist was cut off and observed in the naked eye skin, pathological section and immunohistochemistry of the mice in the experimental group and the control group.

　　Results: (1) There were significant differences among the four groups in the number of days of hair regeneration, the number of days of complete hair regeneration, the time of desquamation, the time of rash appearance, and the number of pores expansion (P<0.01 or P<0.05); ki67:="" there="" was="" no="" significant="" difference="" among="" the="" four="" groups="" p="">0.05).

　　Conclusion: (1) This experiment confirms the view of many researchers that "the rash caused by EGFRIs is an inflammatory reaction"; (2) The rash model is reliable, practical and repeatable. It is suitable for the establishment of a large number of "animal models of rash caused by EGFRIs" and can be popularized for clinical, experimental and research purposes.